TEPNEL LIFE SCIENCES PLC - Preliminary Results 2004 31st March 2005
TEPNEL LIFE SCIENCES PLC ("the Company", AIM:TED) www.tepnel.com
Tepnel's preliminary results for the year ended 31st December 2004
Tepnel Life Sciences provides research products and services to the
fast growing pharmaceutical and biotechnology markets and provides
molecular diagnostic products and services Highlights * Completion
of Tepnel Lifecodes acquisition at a favourable price * Increase in
annual sales from �3.9 million (2003) to �10.2 million (2004) *
Reduction in annual operating losses (pre-exceptional items) from
�2.17 million (2003) to �1.73 million * Secured new equity funding
of �4.2 million (before expenses) * Completion of Diaclone
acquisition Chairman's Statement 2004 was a year of significant
change and growth for Tepnel, with the completion of two
international acquisitions, Tepnel Lifecodes Corporation (formerly
Orchid Diagnostics) in January and Diaclone Research SAS in
December. These marked the Group's entrance into the strategically
important markets of molecular diagnostics and monoclonal antibody
development and production. The acquisition of Tepnel Lifecodes
based in Stamford, Connecticut USA, was completed in January 2004
for an initial consideration of $3.45m. Following a review of the
completion accounts, the consideration was revised downwards to
$2.49m. We are pleased to report that this important new addition
to our Group performed in line with management's expectations for
the year under review. A rapid integration of the business has
allowed us to commence the sale and distribution of our existing
Tepnel DNA purification products and Tepnel Biosystems food safety
tests into continental USA. Tepnel's second acquisition in 2004 was
Diaclone Research SAS in December for a consideration of �2.37
million. The company, located in Besancon, France, produces
monoclonal antibodies for in vitro studies and diagnostic purposes.
Diaclone has strong historical relationships with several major
pharmaceutical companies and this is expected to create
cross-selling opportunities for both our TSS Division and for
Diaclone to build incremental revenues in the future. Tepnel also
secured significant new funding in 2004. A successful round of �
4.2m (before expenses) in November was used to raise the funds
required for the acquisition of Diaclone Research SAS. In addition
the funds will be used for the construction of a biopharmaceutical
facility for the Tepnel Scientific Services business in Livingston,
Scotland. The Company also issued 74.4 million warrants to
subscribe for shares at 6.98 pence per share and raised �0.6
million of equity funding at the beginning of the year through
Cornell Capital Partners Offshore L.P. Poor progress in sales of
our Nucleoplex and Nucleopure systems during the year was a major
disappointment. The Board has decided that these products would
have a better chance of success with a specialist instrument
business and we are actively searching for appropriate
opportunities to sell the instruments operation to such a company.
Alternatively we may choose a partner through whom we would retain
the right to sell reagents to end-users. The Group has since the
year-end ceased the research, development, sales and marketing
activities associated with these two projects and the benefits of
this decision are expected to contribute positively to our
financial results in 2005. Financial results Turnover for the
twelve months ended 31st December 2004 reached �10.2 million from
�5.7 million in the 18 months to 31st December 2003. Turnover in
the calendar year 2004 from activities owned in 2003, grew 4.5% to
�4.04 million (2003 - �3.87 million). Turnover from acquisitions in
the year contributed � 6.15 million (2003: � nil) Operating losses
for the twelve months were �2.28 million (2003 18 months: � 5.94
million) after taking account of exceptional items totalling �0.55
million (2003 18 months: �2.35 million). An exceptional loss was
recognised in the following area during the final six months of the
year: * The lack of progress in sales of the Nucleoplex and
Nucleopure instruments systems has resulted in cessation of
continued research, development, sales and marketing activities
associated with these products. The Company has provided at
year-end a total of �547,000, comprising �506,000 for write-down of
stocks of these two instruments systems and �41,000 for redundancy
costs for people employed directly or indirectly on these projects.
Operating losses pre-exceptional items in calendar year 2004, from
activities owned in 2003, were �1.64 million, a reduction of 24.3%
from the calendar year 2003 loss of �2.17 million. Acquisitions
during the year made an operating loss of �0.09 million (2003:
�nil) The basic loss per share for the year was 1.5 pence (2003 18
months: 5.6 pence). Following the completion of the acquisition of
Diaclone Research, cash balances at 31st December 2004 amounted to
�2.54 million. Net assets at year-end totalled � 7.56 million
(2003: � 5.90 million) Overall, during the last year for Tepnel has
once again demonstrated increased sales and increased gross
profits. In addition, losses before interest, tax and exceptional
items were reduced. Board additions Dr. Andrew Clark joined the
Company as Non-Executive Director in May and brings a wealth of
experience to the Company. Andrew acts as a consultant for
Reabourne Technology Investment Management Ltd, which he co-founded
in 1995. Prior to this role he held several positions including UK
and European Biotechnology Analyst at Barings. Post balance-sheet
events Our new subsidiary in France began the year well by securing
a valuable comprehensive research collaboration with Boehringer
Ingelheim of Germany to develop antibodies for research and
possibly for therapeutic use. Under the terms of the agreement
Diaclone will generate murine monoclonal antibodies that recognise
human immune regulatory cells. The terms of the collaboration also
allow Tepnel to market for research and diagnostic applications
those monoclonal antibodies generated by Diaclone which are not
developed for therapeutic indications by Boehringer Ingelheim.
Future Prospects Following the acquisition of Diaclone Research SAS
in December 2004, our businesses have been restructured into two
divisions: * Research Products and Services; and * Molecular
Diagnostics. The Molecular Diagnostics division comprises the
Tepnel Lifecodes and Tepnel Diagnostics businesses acquired from
Orchid Biosciences in January 2004, whereas the Research Products
and Services division comprises all our other activities including
the newly acquired Diaclone Research SAS. These two divisions and
their related markets we believe offer excellent growth prospects.
Resources for organic growth and further strategic M&A will be
directed towards these markets. All of our UK companies, with the
exception of Tepnel Life Sciences plc, traded profitably during
2004. Certain ongoing annual payroll costs estimated to be around
�250,000 associated with the instrument side of Tepnel Life
Sciences plc have now been eliminated. This is expected to have a
positive impact on financial results for the year ended 31st
December 2005. Acquisitions during the year, whilst loss-making,
are expected to achieve operating profitability in 2005. The key
objective for the Tepnel Group is to reach sustainable
profitability at the earliest opportunity. Both of the new
divisions and their constituent parts are committed to further
improvements in financial performance in 2005. Current Trading
Tepnel has made a solid start to the year. The Board is confident
of reporting further progress towards profitability in 2005. Alec
Craig Non-Executive Chairman 31st March 2005 References to the
figures for the calendar year ended 31 December 2003 are contained
within note 6. Consolidated Profit & Loss account for the year
ended 31 December 2004 Unaudited Audited Continuing Activities
Consolidated Acquisitions Year ended 18 Months 31 ended December 31
2004 December 2003 Notes �'000 �'000 �'000 �'000 Turnover 1 6,149
4,044 10,193 5,676 Cost of sales (3,687) (1,780) (5,467) (3,041)
Gross profit 2,462 2,264 4,726 2,635 Other administrative (443)
(2,279) (2,722) (3,320) expenses Exceptional items 2 - (547) (547)
(2,348) Total administrative (443) (2,826) (3,269) (5,668) expenses
Sales and marketing (1,293) (892) (2,185) (1,295) Research and
development (820) (733) (1,553) (1,613) Total expenses (2,556)
(4,451) (7,007) (8,576) Operating loss (94) (2,187) (2,281) (5,941)
Bank interest receivable 43 100 Interest payable (23) (41) Loss on
ordinary (2,261) (5,882) activities before taxation Taxation on
loss on 19 221 ordinary activities Loss on ordinary (2,242) (5,661)
activities after taxation Basic loss per share 5 1.5p 5.6p Diluted
loss per share 5 1.5p 5.6p Consolidated Balance Sheet as at 31
December 2004 Unaudited Audited Notes 31 31 December December 2004
2003 �'000 �'000 Fixed assets Intangible 1,882 - Tangible 1,851
1,171 3,733 1,171 Current assets Stocks 2,279 995 Debtors 2,932
1,481 Cash at bank and in hand 2,542 4,244 7,753 6,720 Creditors:
amounts falling (3,927) (1,859) due within one year Net current
assets 3,826 4,861 Total assets less current 7,559 6,032
liabilities Creditors: amounts falling - (137) due after more than
one year Net Assets 7,559 5,895 Represented by: Called up share
capital 2,129 1,337 Share premium 33,588 30,438 Profit and loss
account (28,158) (25,880) 4 7,559 5,895 Consolidated Statement of
Total Recognised Gains and Losses Unaudited Audited Year ended 18
months 31 December ended 31 2004 December 2003 �'000 �'000 Loss for
the period (2,242) (5,661) Currency translation differences on (36)
- foreign currency net investments Total losses recognised (2,278)
(5,661) Consolidated Cash Flow Statement for the year ended 31
December 2004 Unaudited Audited Year ended 31 18 months December
2004 ended 31 December 2003 �'000 �'000 Net cash outflow from
operating (1,107) (3,089) activities Return on investments and
servicing 20 59 of finance Corporation tax refund 180 323 Capital
expenditure (317) (223) Acquisitions (3,838) - Net cash outflow
before financing (5,062) (2,930) Management of liquid resources -
2,802 Financing 3,310 3,875 (Decrease) / Increase in cash (1,752)
3,747 Unaudited Audited Year ended 31 18 months December 2004 ended
31 December 2003 Reconciliation of operating loss to �'000 �'000
net cash outflow from operating activities: Operating loss (2,281)
(5,941) Depreciation 596 1,022 Amortisation 56 1,783
Decrease/(Increase) in stocks 572 (155) Decrease/(Increase) in
debtors 228 (73) (Decrease)/Increase in creditors (227) 255
Decrease in current asset investment - 20 Other non-cash movements
(51) - Net cash outflow from operating (1,107) (3,089) activities
Unaudited Audited Year ended 31 18 months December 2004 ended 31
December 2003 Reconciliation of net cash flow to �'000 �'000
movement in net funds: (Decrease)/Increase in cash (1,752) 3,747
Cash inflow from short term deposits - (2,802) Cash outflow from
lease financing 142 250 Exchange differences on (37) -
retranslation Change in net funds resulting from (1,647) 1,195 cash
flow New finance leases - (499) Net funds at beginning of period
3,968 3,272 Net funds at end of period 2,321 3,968 Notes 1
Consolidated turnover for the year ended 31 December 2004 Unaudited
Audited Year ended 18 months 31 December ended 31 2004 December
2003 �'000 �'000 United Kingdom 3,577 4,137 Rest of Europe 2,400
831 Americas 3,350 472 Asia 472 156 Rest of World 394 80 10,193
5,676 Segmental analysis Following the acquisition of Tepnel
Lifecodes, Tepnel Diagnostics and Diaclone Research, the Board
believe there to be two distinct business classes being, Research
Products and Services, and Molecular Diagnostics. The businesses
included in the comparative figures form part of Research, Products
and Services. Class of business Unaudited Audited 2004 Class of
business 2003 Class of business Research Research Products Products
and Molecular and Molecular Services Diagnostics Total Services
Diagnostics Total �'000 �'000 �'000 �'000 �'000 �'000 TURNOVER
Total sales to third 4,068 6,125 10,193 5,676 - 5,676 parties LOSS
BEFORE TAXATION (2,196) (65) (2,261) (5,882) - (5,882) NET ASSETS
Segment net assets 7,689 (130) 7,559 5,895 - 5,895 Geographical
segments Unaudited Audited 2004 Geographical segments 2003
Geographical segments UK EU US Asia Rest Group UK EU US Asia Rest
Group of of World World �'000 �'000 �'000 �'000 �'000 �'000 �'000
�'000 �'000 �'000 �'000 �'000 TURNOVER Sales to third 3,577 2,400
3,350 472 394 10,193 4,137 831 472 156 80 5,676 parties by
geographical destination Sales to third 5,295 25 4,873 - - 10,193
5,676 - - - - 5,676 parties by geographical origin LOSS BEFORE
TAXATION Segmental loss (2,094) (29) (138) - - (2,261) (5,882) - -
- - (5,882) NET ASSETS Segment net 7,889 (30) (300) - - 7,559 5,895
- - - - 5,895 assets 2 Exceptional items Unaudited Audited Year
ended 31 18 months December 2004 ended 31 December 2003 �'000 �'000
Fixed asset impairment - 528 Goodwill impairment - 1,642 Foreign
currency exchange loss - 178 Redundancy costs1 41 - Costs relating
to restructuring and 506 - relocation1 547 2,348 1 The lack of
progress in sales of the Nucleoplex and Nucleopure instruments
systems has resulted in cessation of continued research,
development, sales and marketing activities associated with these
products. The Company has provided at year-end a total of �547,000,
comprising �506,000 for write down of stocks of the Nucleopure and
Nucleoplex instruments systems held at 31 December 2004 and �41,000
for redundancy costs for people employed directly or indirectly on
these projects. 3 Fair value of assets acquired Tepnel Life
Sciences PLC acquired Tepnel Lifecodes and Tepnel Diagnostics,
formerly Orchid Diagnostics, on 21 January 2004 and Diaclone on 15
December 2004. Unaudited Purchase of subsidiary Orchid Diaclone
Total undertakings Diagnostics �'000 �'000 �'000 Tangible fixed
assets 929 18 947 Stocks 1,321 534 1,855 Debtors 953 223 1,176
Prepayments 146 43 189 Cash at bank and in hand 13 37 50 Creditors
(1,920) (378) (2,298) Net assets acquired 1,442 477 1,919 Goodwill
616 1,353 1,969 2,058 1,830 3,888 less costs of acquisition (598)
(81) (679) Satisfied by cash 1,460 1,749 3,209 Unaudited
Provisional fair value of Fair value adjustments assets acquired
(Orchid Diagnostics): Book value Revaluations Accounting Fair value
policy alignment �'000 �'000 �'000 �'000 Tangible fixed assets
1,897 - (968) 929 Stocks 1,395 - (74) 1,321 Debtors 982 - (29) 953
Prepayments 171 - (25) 146 Cash at bank and in hand 13 - - 13
Creditors (1,748) - (172) (1,920) 2,710 - (1,268) 1,442 Unaudited
Provisional fair value of Fair value adjustments assets acquired
(Diaclone): Book value Revaluations Accounting Fair value policy
alignment �'000 �'000 �'000 �'000 Tangible fixed assets 18 - - 18
Stocks 807 - (273) 534 Debtors 223 - - 223 Prepayments 43 - - 43
Cash at bank and in hand 37 - - 37 Creditors (378) - - (378) 750 -
(273) 477 Unaudited Total provisional fair Fair value adjustments
value of assets acquired: Book value Revaluations Accounting Fair
value policy alignment �'000 �'000 �'000 �'000 Tangible fixed
assets 1,915 - (968) 947 Stocks 2,202 - (347) 1,855 Debtors 1,205 -
(29) 1,176 Prepayments 214 - (25) 189 Cash at bank and in hand 50 -
- 50 Creditors (2,126) - (172) (2,298) 3,460 - (1,541) 1,919 4
Reconciliation of movement of shareholders funds Unaudited Audited
Year ended 31 18 months ended December 2004 31 December 2003 �'000
�'000 Loss for the year/period and net (2,242) (5,661) increase in
shareholders' deficit Other recognised losses for the (36) - year
Issue of shares (including premium) 3,942 4,224 Net
additions/(reduction) to equity 1,664 (1,437) shareholders' funds
Opening equity shareholders funds 5,895 7,332 Closing equity
shareholders funds 7,559 5,895 5 Loss per share Unaudited Audited
Year ended 31 18 months December 2004 ended 31 December 2003 Shares
in issue (weighted average) 148,403,632 101,402,875 Loss for period
�2,242,000 �5,661,000 Loss per share 1.5p 5.6p Diluted loss per
share 1.5p 5.6p 6 Reconciliation of results for the 12 months ended
31 December 2003 Unaudited Audited Unaudited 6 months ended 18
months ended 12 months ended 31 December 31 December 31 December
2002 2003 2003 �000s �000s �000s Sales 1,805 5,676 3,871 Cost of
Sales (1,096) (3,041) (1,945) Gross Profit 709 2,635 1,926
Operating Expenses: Research and Development (515) (1,613) (1,098)
Sales and Marketing (469) (1,295) (826) Administrative expenses
(1,153) (3,320) (2,167) (excluding exceptional items) Exceptional
items - (2,348) (2,348) (Administrative expenses) Total Operating
Expenses (2,137) (8,576) (6,439) Operating loss before interest
(1,428) (5,941) (4,513) Interest 54 100 46 receivable Interest
payable (1) (41) (40) Loss before tax (1,375) (5,882) (4,507)
Taxation 57 221 164 Loss after tax (1,318) (5,661) (4,343)
Operating Loss before (1,428) (3,593) (2,165) exceptional items 7
The preliminary results for the year ended 31 December 2004 have
been approved by the Directors. Our Auditors have not issued a
report on the results for the year ended 31 December 2004 under
Section 235 of the Companies Act 1985. The accounts for the year
ended 31 December 2004 will be delivered to the Registrar of
Companies in due course. The financial information set out above
does not constitute statutory accounts within the meaning of
Section 240 of the Companies Act 1985. The audited information as
at 31 December 2003 has been extracted from the statutory accounts
for the period ended 31st December 2003, which have been delivered
to the Registrar of Companies and whilst the audit opinion was
unqualified, the Auditors included an explanatory paragraph
regarding going concern. 8 The directors do not recommend the
payment of a final dividend. 9 The operating loss is arrived at
after writing off research and development expenditure and
exceptional items to the profit and loss account in the period in
which it was incurred 10 The accounting policies used are
consistent with those applied in the latest published company
accounts. END DATASOURCE: TEPNEL LIFE SCIENCES PLC
Copyright
Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024